Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Eduard, Cmunt"'
Autor:
Petra Belohlavkova, Daniela Zackova, Hana Klamova, Edgar Faber, Michal Karas, Lukas Stejskal, Eduard Cmunt, Olga Cerna, Ivana Jeziskova, Katerina Machova Polakova, Pavel Zak, Tereza Jurkova, Marika Chrapava, Jiri Mayer
Publikováno v:
Cancer Medicine, Vol 13, Iss 17, Pp n/a-n/a (2024)
Abstract Background To evaluate the outcomes of first‐line imatinib versus nilotinib treatment for chronic myeloid leukemia in the chronic phase (CML‐CP) in real‐world clinical practice. Methods A propensity score analysis was performed to elim
Externí odkaz:
https://doaj.org/article/a3f1e095df1743329fc066dd5daac827
Autor:
Lukas Semerad, Daniela Žáčková, Petra Belohlavkova, Jaroslava Voglova, Pavel Žák, Edgar Faber, Tomas Papajik, Ivana Skoumalova, Michal Karas, Pavel Jindra, Hana Klamová, Cyril Salek, Dana Srbová, Hana Zizkova, Lukas Stejskal, Olga Cerna, Eduard Cmunt, Petra Cicatkova, Anezka Kvetkova, Tomas Hornak, Ivana Jeziskova, Tomas Jurcek, Barbora Weinbergerová, Jirina Prochazkova, Katerina Machova Polakova, Adam Svobodnik, Radka Stepanova, Jiri Mayer
Publikováno v:
HemaSphere, Vol 7, p e70530bf (2023)
Externí odkaz:
https://doaj.org/article/e7c94ed4ac6546329523a51b5039e6a2
Autor:
Tomas Kozak, David Belada, Yvona Brychtová, Martin Brejcha, Lukas Stejskal, Martin Spacek, Heidi Mocikova, Jana Zuchnická, Martin Simkovic, Renata Urbanova, Irena Zygulova, Michael Doubek, Eduard Cmunt, Lukas Smolej
Publikováno v:
British Journal of Haematology. 193:769-778
Therapeutic options used to be very limited for treatment-naive elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL) before the introduction of chemo-immunotherapy. Because dose-reduced fludarabine-based r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4f89cae46e416b16be52e4e44aac2f3
https://doi.org/10.1111/bjh.17373
https://doi.org/10.1111/bjh.17373
Autor:
Hana Klamová, Kateřina Machová Poláková, Jan Mužík, Zdeněk Ráčil, Daniela Žáčková, Kateřina Steinerová, Michal Karas, Edgar Faber, Eva Demečková, Zuzana Michalovičová‐Sninská, Jaroslava Voglová, Ľudmila Demitrovičová, Eva Mikušková, Elena Tóthová, Juraj Chudej, Imrich Markuljak, Eduard Cmunt, Jana Moravcová, Dana Dvořáková, Kyra Michalová, Marie Jarošová, Markéta Marková Šťastná, Petr Cetkovský, Ladislav DuŠek, Vladimír Koza, Marek Trněný, Karel Indrák
Publikováno v:
Cancer Medicine, Vol 2, Iss 2, Pp 216-225 (2013)
Abstract We evaluated responses to the treatment and long‐term outcomes of chronic myeloid leukemia patients treated with imatinib as first‐line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors
Externí odkaz:
https://doaj.org/article/3352c3f69ea544aab068556ac3c96068
Autor:
Edgar Faber, Eduard Cmunt, Jaroslava Voglová, Michal Karas, Peter Rohon, Pavel Zak, Zlatuse Kristkova, Karel Indrak, Katerina Steinerova, Marek Trneny, Tomas Papajik, Filip Vrbacky, Tereza Nečasová, I. Skoumalová, Petra Belohlavkova
Publikováno v:
Leukemia Research. 81:67-74
We retrospectively evaluated the role of age and dosage in 372 CML patients (170 women, 202 men) treated with first-line imatinib (IMA) from the records of the CAMELIA registry. The median follow-up of the patients was 82.3 (18.0-177.3) months. The t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ec7559451ce973613d7dc33fddfbb96c
https://doi.org/10.1016/j.leukres.2019.04.011
https://doi.org/10.1016/j.leukres.2019.04.011
Autor:
Anežka Kvetková, Jitka Rychlíčková, Eduard Cmunt, Tomáš Jurček, Regina Demlová, Lukáš Semerád, Jiří Mayer, Kateřina Machová Poláková, Radka Štěpánová, Daniela Žáčková, Ivana Ježíšková, Edgar Faber, Michal Karas, Ondřej Wiewiorka, Petra Čičátková, Jiřina Procházková, Tomáš Horňák, Marek Borský, Lukas Stejskal, Petra Bělohlávková, O. Černá, Adam Svobodník, Hana Klamova
Publikováno v:
Blood. 138:3606-3606
Background. Treatment-free remission (TFR) has become a new treatment goal for chronic myeloid leukemia (CML) patients. However, usually abrupt tyrosine kinase inhibitors (TKIs) therapy discontinuation has been successful only in about half of eligib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e988edf24f9c19191d0a87c72eabc49e
https://doi.org/10.1182/blood-2021-146221
https://doi.org/10.1182/blood-2021-146221
Autor:
Lubomir Minarik, Anna Jonasova, Eduard Cmunt, Zuzana Zemanova, Radana Neuwirtova, Monika Belickova, Helena Polackova, Ota Fuchs, M. Siskova, Kyra Michalova, Alena Moudra, Tomas Stopka
Publikováno v:
Leukemia research. 69
Lenalidomide therapy represents meaningful progress in the treatment of anemic patients with myelodysplastic syndromes with del(5q). We present our initial lenalidomide experience and the positive effect of combining erythropoietin and steroids with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::408871c7cacb64e676e287701d7b7783
https://pubmed.ncbi.nlm.nih.gov/29614393
https://pubmed.ncbi.nlm.nih.gov/29614393
Autor:
Daniela Zackova, Jaroslava Voglová, Katerina Machova Polakova, Karel Indrak, Jiri Mayer, Edgar Faber, Ludmila Demitrovicova, Jan Muzik, Imrich Markuljak, Juraj Chudej, Eduard Cmunt, Ladislav Dušek, Hana Klamova, Elena Tóthová, Zdenek Racil, Michal Karas, Tomas Kozak, Marie Jarošová, Eva Janoušová, Tomáš Pavlík, Eva Demečková
Publikováno v:
American Journal of Hematology. 88:790-797
Using the data of 723 chronic myeloid leukemia (CML) patients in the chronic phase, we analyzed the prognostic value of the Sokal, Euro, and EUTOS scores as well as the level of BCR-ABL1 and the achievement of complete cytogenetic response (CCgR) at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::946fa9ab3eb4fdbedd38455aed2dfdaa
https://doi.org/10.1002/ajh.23508
https://doi.org/10.1002/ajh.23508
Autor:
Marek Trněný, Michal Karas, Imrich Markuljak, Kateřina Machová Poláková, Jaroslava Voglová, Karel Indrak, Jan Mužík, Kyra Michalova, Marie Jarošová, Markéta Marková Šťastná, Vladimir Koza, Zdeněk Ráčil, Kateřina Steinerová, Elena Tóthová, Ľudmila Demitrovičová, Eva Mikuskova, Eva Demečková, Eduard Cmunt, Edgar Faber, Daniela Žáčková, Ladislav Dušek, Dana Dvořáková, Zuzana Michalovičová-Sninská, Hana Klamova, Juraj Chudej, Petr Cetkovský, Jana Moravcová
Publikováno v:
Cancer Medicine. 2:216-225
We evaluated responses to the treatment and long-term outcomes of chronic myeloid leukemia patients treated with imatinib as first-line treatment in routine clinical setting from two countries with centralized tyrosine kinase inhibitors (TKIs) treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1de8c83512329e9d750d3b06a947baec
https://doi.org/10.1002/cam4.59
https://doi.org/10.1002/cam4.59
Autor:
Eduard Cmunt, Ludmila Demitrovicova, Jaroslava Voglová, Imrich Markuljak, Juraj Chudej, Tomas Kozak, Edgar Faber, Marie Jarošová, Karel Indrak, Vladimir Koza, Elena Tóthová, Ladislav Dušek, Eva Demečková, Jan Mužík
Publikováno v:
European Journal of Haematology. 87:157-168
Most results on the treatment of chronic myeloid leukaemia (CML) with imatinib were obtained from clinical trials that may differ from the routine practice. We report the results of treatment of consecutive patients with CML at ten major centres duri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::536a4039579cc04e005b806d36c6fa0f
https://doi.org/10.1111/j.1600-0609.2011.01637.x
https://doi.org/10.1111/j.1600-0609.2011.01637.x